GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Luminex Corp (NAS:LMNX) » Definitions » Earnings per Share (Diluted)

Luminex (Luminex) Earnings per Share (Diluted) : $0.51 (TTM As of Mar. 2021)


View and export this data going back to 2000. Start your Free Trial

What is Luminex Earnings per Share (Diluted)?

Luminex's Earnings per Share (Diluted) for the three months ended in Mar. 2021 was $0.19. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 was $0.51.

Luminex's EPS (Basic) for the three months ended in Mar. 2021 was $0.19. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2021 was $0.51.

Luminex's EPS without NRI for the three months ended in Mar. 2021 was $0.19. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2021 was $0.51.

During the past 3 years, the average EPS without NRIGrowth Rate was -22.50% per year.

During the past 13 years, Luminex's highest 3-Year average EPS without NRI Growth Rate was 98.00% per year. The lowest was -23.00% per year. And the median was 24.90% per year.


Luminex Earnings per Share (Diluted) Historical Data

The historical data trend for Luminex's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luminex Earnings per Share (Diluted) Chart

Luminex Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.32 0.67 0.41 -0.09 0.32

Luminex Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.27 0.04 0.01 0.19

Competitive Comparison of Luminex's Earnings per Share (Diluted)

For the Medical Instruments & Supplies subindustry, Luminex's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luminex's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Luminex's PE Ratio distribution charts can be found below:

* The bar in red indicates where Luminex's PE Ratio falls into.



Luminex Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Luminex's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2020 is calculated as

Diluted Earnings Per Share (A: Dec. 2020 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(15.17-0)/45.820
=0.33

Luminex's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2021 is calculated as

Diluted Earnings Per Share (Q: Mar. 2021 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(9.082-0)/46.675
=0.19

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Luminex  (NAS:LMNX) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Luminex Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Luminex's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Luminex (Luminex) Business Description

Traded in Other Exchanges
N/A
Address
12212 Technology Boulevard, Suite 130, Austin, TX, USA, 78727
Luminex Corp develops, manufactures, and sells proprietary biological testing technologies and products to testing laboratories. It primarily serves the life sciences industries by selling products used by laboratory professionals and clinical laboratories in performing diagnostics, drug research and discovery, and clinical tests on patients. Luminex's market segments mainly include Infectious disease, Personalized medicine, and Human genetics. It offers various solutions in diverse markets, including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. The vast majority of the company's revenue is earned in the United States. The products offered are xMAP Products, ARIES Products and VERIGENE Products, among others.
Executives
Harriss T Currie officer: SVP, Finance & CFO 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Todd C. Bennett officer: SVP, Global Sales & Cust Ops 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Stephen L. Eck director 12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Edward A Ogunro director
Eric Shapiro officer: SR VP, GLOBAL MARKETING 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Nachum Shamir director, officer: President & CEO 12212 TECHNOLOGY BLVD, AUSTIN TX 78727
Rew Richard W. Ii officer: SVP, Gen Counsel & Corp Secy 7000 WEST WILLIAM CANNON, BUILDING ONE, AUSTIN TX 78735
Nancy Fairchild officer: SVP, Human Resources 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
G Walter Lowenbaum director C/O 3D SYSTEMS CORPORATION, 333 THREE D SYSTEMS CIRCLE, ROCK HILL SC 29730
Randall Myers officer: SVP, Global Mfg and Quality 12212 TECHNOLOGY BOULEVARD AUSTIN TX 78727
Charles J. Collins officer: SR VP, R&D - US 12212 TECHNOLOGY BLVD. AUSTIN TX 78727
Dijuana K Lewis director 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Jim D Kever director C/O 3D SYSTEMS, 26081 AVENUE HALL, VALENCIA CA 91355
Thomas W Erickson director OMEGA HEALTHCARE INVESTORS INC, 900 VICTORS WAY STE. 350, AMM ARBER MI 48108
Kenneth A Samet director 800 KING FARM BOULEVARD, 4TH FLOOR, ROCKVILLE MD 20850

Luminex (Luminex) Headlines

From GuruFocus

Middlesex Water Set to Join S&P SmallCap 600

By PRNewswire PRNewswire 07-12-2021

Luminex Corporation Declares Fourth Quarter Cash Dividend

By PRNewswire PRNewswire 12-07-2020

Luminex Corporation Declares Second Quarter Cash Dividend

By PRNewswire PRNewswire 05-20-2021